Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders

Eberhard, Jonas; Lindström, Eva; Holstad, Maria; Levander, Sten

doi:10.1111/j.1600-0447.2006.00897.x

Cited by 51 publications

(46 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many if not all of the data are of too short a duration to make definitive statements regarding the persistence of hyperprolactinemia during treatment with antip sychotics [Bushe et al 2008]. However, there is a 5year naturalistic study of risperidone that suggests that prolactin levels may decrease over time [Eberhard et al 2007]. In the present study we observed a significant increase in prolactin levels both in women and men in concordance with the literature data.…”

Section: Discussionsupporting

confidence: 89%

Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study

Kotan¹,

Ertepe²,

Akkaya³

et al. 2011

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Abstract:Background: Amisulpride is a second-generation antipsychotic which has been proved to be effective in the control of both positive and negative symptoms of schizophrenia. In this study we aimed to determine metabolic, endocrinologic and cardiac effects of amisulpride commonly used in our clinical practice. Methods: A total of 18 patients (11 males, 7 females) diagnosed with schizophrenia received amisulpride at the dosage of 800 mg/day and were followed up for 24 weeks. Positive and negative psychotic symptoms, extrapyramidal and sexual side effects, metabolic, endocrinologic and cardiac parameters were evaluated at regular intervals. Results: Significant improvement in both positive and negative symptoms was observed in patients starting from the second week of treatment. Prolactin levels increased significantly both in men and women starting from the measurement on day 4. Prolactin elevation was significantly higher in women than in men. Increase in total cholesterol level became significant at week 24. No other significant difference was observed between weeks 1 and 24 regarding the other parameters. Conclusions:The clinical data from the present study supports the fact that amisulpride is an effective and safe antipsychotic drug, but elevates prolactin levels in both sexes.

show abstract

Section: Discussionsupporting

confidence: 89%

Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study

Kotan¹,

Ertepe²,

Akkaya³

et al. 2011

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…27 The most common adverse events after the use of AAP were two: drowsiness and weight gain. Risperidone was more frequently associated with increases in prolactin levels, 40 and the use of ziprasidone was only partially associated with weight gain. 52 Data about quetiapine and aripiprazole are still too limited to provide a minimally consistent evaluation of their adverse events.…”

Section: Risperidonementioning

confidence: 98%

“…39 The comparison with other AAPs revealed that risperidone was the medication that resulted in the highest prolactin elevation among adults with schizophrenia (n = 218) in a study that followed up patients for five years. 40 In a study that compared the use of olanzapine with that of haloperidol in 12 children with autism for six weeks, olanzapine was more efficacious in the control of aggression, but resulted in greater weight gain. 44 In some emergency situations that require aggression control, the IM injection of a rapid-acting medication may be necessary.…”

Section: Risperidonementioning

confidence: 99%

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations

Teixeira

Jacintho

Celeri

et al. 2013

Trends Psychiatry Psychother.

View full text Add to dashboard Cite

Objective: To review the literature about the use of atypical antipsychotics in the treatment of pathological aggression in children and adolescents. Method: The databases MEDLINE, SciELO, and LILACS were searched for publications in Portuguese or English from 1992 to August 2011 using the following keywords: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behavior, aggression, and violent behavior. Results: Sixty-seven studies of good methodological quality and clinical interest and relevance were identified. Studies including children and adolescents were relatively limited, because few atypical antipsychotics have been approved by the Food and Drug Administration (FDA). All the medications included in this review (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole and clozapine) have some effectiveness in treating aggression in children and adolescents, and choices should be based on clinical indications and side effects. Conclusions: There are few studies about the effectiveness and safety of atypical antipsychotics for the pediatric population, and further randomized controlled studies with larger groups of patients and more diagnostic categories, such as severe conduct disorder and oppositional defiant disorder, should be conducted to confirm the results reported up to date and to evaluate the impact of long-term use. Keywords: Aggression, violence, atypical antipsychotics, behavioral disorders, children, adolescents. ResumoObjetivo: Realizar uma revisão sistemática da literatura científica sobre o uso de antipsicóticos atípicos (APAs) no tratamento da agressividade patológica em crianças e adolescentes. Método: Foi realizada busca eletrônica nas bases de dados MEDLINE, SciELO e LILACS, de 1992 a agosto 2011, considerando artigos publicados em língua inglesa e portuguesa. Foram utilizadas associações das seguintes expressões: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behaviour, aggression e violent behavior. Resultados: Foram identificados 67 artigos de boa qualidade metodológica, de relevância e interesse clínico para o tema em foco. De modo geral, os estudos são relativamente limitados para esta faixa etária, resultado do fato de poucos APAs terem sido aprovados pela Food and Drug Administration (FDA). Dentre as medicações consideradas nesta revisão (risperidona, olanzapina, quetiapina, ziprazidona, aripiprazol e clozapina), todas elas podem ter alguma efetividade no tratamento da agressividade em crianças e adolescentes, ficando a escolha baseada na indicação clínica e perfil de efeitos colaterais. Conclusão: O número ainda limitado de estudos acerca da efetividade e segurança na população pediátrica demanda pesquisas futuras com grupos maiores de pacientes e com mais categorias diagnósticas (como, por exemplo, as formas graves de transtorno de conduta e transtorno desafiador de oposição), desenhadas de forma randomizada e controlada. Assim poderão ser confirmados os achados até o momento e o impacto do uso em lo...

show abstract

“…The course and persistence of HPL in relation to antipsychotic use overtime remains a complex question, and one with which the literature is limited by a lack of prospective studies (Eberhard et al, 2007;Pérez-Iglesias et al, 2012). However, our naturalistic study provides further evidence that rates of HPL do decline over the first year of illness, but that HPL persists with all antipsychotics used, with higher rates of sustained HPL seen with amisulpride, risperidone and FGAs.…”

Section: Antipsychotics and Hplmentioning

confidence: 74%

Hyperprolactinaemia in first episode psychosis - A longitudinal assessment

Lally

Ajnakina

Stubbs

et al. 2017

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders

Abstract: Risperidone induces a higher prolactin elevation than other atypical antipsychotics, but the effect adapts over time. Prolactin was not associated with expected side effects (e.g. sexual, mental, or weight gain).

Cited by 51 publications

References 40 publications

Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study

Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations

Hyperprolactinaemia in first episode psychosis - A longitudinal assessment

Contact Info

Product

Resources

About